3 Formulation Major, Infusion Set Maker and Pizza Chain Stocks With a Strong Future Roadmap: Aurobindo Pharma, Poly Medicure and Jubilant FoodWorks
- October 19, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Aurobindo Pharma Rs 1,666.90, P/E 25.46. Poly Medicure Rs 1,593.80, P/E 51.87. Jubilant FoodWorks Rs 417.95, P/E 62.77. Closing prices of 14 Oct 2026.
Quick Answer
Formulation major, infusion set maker and pizza chain stocks with the clearest long-term roadmaps today include Aurobindo Pharma in generic formulations and active ingredients sold in the US, Europe and emerging markets, Poly Medicure in medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets and Jubilant FoodWorks in Domino’s Pizza stores across India and neighbouring markets, along with newer food brands. FY26 revenue growth was 5.6% at Aurobindo Pharma, 13.4% at Poly Medicure and 17.2% at Jubilant FoodWorks. P/E stands at 25.46 for Aurobindo Pharma (industry 37.59), 51.87 for Poly Medicure (industry 62.79) and 62.77 for Jubilant FoodWorks (industry 61.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Formulation major, infusion set maker and pizza chain stocks give investors exposure to medicines, hospital supplies and eating out. Volumes, export demand and margins decide how much of that demand turns into profit.
Readers comparing formulation major, infusion set maker and pizza chain stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.
This list covers three formulation major, infusion set maker and pizza chain stocks: Aurobindo Pharma for generic formulations and active ingredients sold in the US, Europe and emerging markets, Poly Medicure for medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets and Jubilant FoodWorks for Domino’s Pizza stores across India and neighbouring markets, along with newer food brands. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Formulation Major, Infusion Set Maker and Pizza Chain Stocks?
Formulation major, infusion set maker and pizza chain stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Formulation Major, Infusion Set Maker and Pizza Chain Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three formulation major, infusion set maker and pizza chain stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,666.90 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
| Poly Medicure | 1,593.80 | 16,231 | 51.87 | 62.79 | 10.37% | 0.11 |
| Jubilant FoodWorks | 417.95 | 28,248 | 62.77 | 61.79 | 18.69% | 2.14 |
Among healthcare and consumer stocks, valuations sit close to their industry P/E multiples.
Why Do Formulation Major, Infusion Set Maker and Pizza Chain Stocks Have a Strong Roadmap in India?
Formulation major, infusion set maker and pizza chain stocks have a strong roadmap in India because generic drug demand overseas, hospital device use and more eating out keep adding volumes for these firms. Three drivers stand out.
- Generic demand: Overseas markets buy affordable formulations and ingredients.
- Hospital demand: Hospitals buy infusion, catheter and dialysis products.
- Eating out: Families order from pizza and food chains.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
Poly Medicure: Medical Devices Build the Next Leg
Poly Medicure’s roadmap rests on medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets, with rising healthcare consumption and export demand supporting growth.
Revenue grew from Rs 960.97 crore in FY22 to Rs 1,995.34 crore in FY26, a 107.6% rise, and FY26 revenue was 13.4% higher than FY25. FY26 net profit was Rs 320.73 crore. In Q1 FY27, revenue grew 25.5% to Rs 558.79 crore. Operating margin was 27.65% in FY26.
Debt to equity is 0.11 and return on equity is 10.37%. FY26 operating cash flow was Rs 246.37 crore against capital expenditure of Rs 308.39 crore. Poly Medicure paid a dividend of Rs 3.5 per share for FY26, a yield of 0.22%. At a P/E of 51.87 against an industry P/E of 62.79, the stock trades below its industry multiple.
What to watch: The P/E of 51.87 against an industry P/E of 62.79 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Jubilant FoodWorks: Domino’s Store Network Anchors the Roadmap
Jubilant FoodWorks’ roadmap rests on Domino’s Pizza stores across India and neighbouring markets, along with newer food brands, with store additions and delivery reach supporting sales.
Revenue grew from Rs 4,437.48 crore in FY22 to Rs 9,586.64 crore in FY26, a 116.0% rise, and FY26 revenue was 17.2% higher than FY25. FY26 net profit rose 54.4% to Rs 386.03 crore. In Q1 FY27, revenue grew 13.6% to Rs 2,588.34 crore, and net profit rose 6.0% to Rs 100.03 crore. Operating margin was 20.96% in FY26 and 20.37% in Q1 FY27 against 20.21% a year earlier.
Debt to equity is 2.14 and return on equity is 18.69%. FY26 operating cash flow was Rs 1,893.55 crore against capital expenditure of Rs 1,009.93 crore. Jubilant FoodWorks paid a dividend of Rs 1.2 per share for FY26, a yield of 0.28%. At a P/E of 62.77 against an industry P/E of 61.79, the stock trades in line with its industry multiple.
What to watch: Debt to equity of 2.14 is on the higher side, and net profit margin is only 4.0%, so small cost changes move earnings.
Best Formulation Major, Infusion Set Maker and Pizza Chain Stocks in India: Aurobindo Pharma vs Poly Medicure vs Jubilant FoodWorks on Key Financials
Among the best formulation major, infusion set maker and pizza chain stocks in India, Aurobindo Pharma leads on the lowest P/E; Poly Medicure leads on FY26 operating margin and Q1 FY27 revenue growth; Jubilant FoodWorks leads on FY26 revenue growth and return on equity. The table puts the numbers side by side.
| Metric | Aurobindo Pharma | Poly Medicure | Jubilant FoodWorks |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 34,145.17 | 1,995.34 | 9,586.64 |
| FY26 revenue growth | 5.6% | 13.4% | 17.2% |
| FY26 net profit (Rs Cr) | 3,502.97 | 320.73 | 386.03 |
| FY26 operating profit margin | 21.61% | 27.65% | 20.96% |
| Q1 FY27 revenue growth (YoY) | 18.1% | 25.5% | 13.6% |
| Return on equity | 9.25% | 10.37% | 18.69% |
| P/E ratio | 25.46 | 51.87 | 62.77 |
| Debt to equity | 0.21 | 0.11 | 2.14 |
| Dividend yield | 0.25% | 0.22% | 0.28% |
| FY26 operating cash flow (Rs Cr) | 5,526.37 | 246.37 | 1,893.55 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Formulation Major, Infusion Set Maker and Pizza Chain Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen formulation major, infusion set maker and pizza chain stocks and shortlist formulation major, infusion set maker and pizza chain stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Formulation Major, Infusion Set Maker and Pizza Chain Stocks
- Debt and cash flow: Jubilant FoodWorks has debt to equity of 2.14.
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma, Poly Medicure and Jubilant FoodWorks live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare and consumer stocks cover generics, medical devices and restaurants. Aurobindo Pharma leads on the lowest P/E; Poly Medicure leads on FY26 operating margin and Q1 FY27 revenue growth; Jubilant FoodWorks leads on FY26 revenue growth and return on equity.
Across formulation major, infusion set maker and pizza chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the formulation major, infusion set maker and pizza chain stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Formulation Major, Infusion Set Maker and Pizza Chain Stocks
Which are the best formulation major, infusion set maker and pizza chain stocks in India with a strong roadmap?
Ans. Aurobindo Pharma, Poly Medicure and Jubilant FoodWorks stand out for their roadmaps in generics, medical devices and restaurants. FY26 revenue growth was 5.6% at Aurobindo Pharma, 13.4% at Poly Medicure and 17.2% at Jubilant FoodWorks, and return on equity ranges from 9.25% to 18.69%.
Is Aurobindo Pharma a good stock to buy now?
Ans. Aurobindo Pharma has a debt to equity ratio of 0.21, a return on equity of 9.25% and a P/E of 25.46 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Aurobindo Pharma, Poly Medicure and Jubilant FoodWorks?
Ans. The P/E ratio is 25.46 for Aurobindo Pharma (industry 37.59), 51.87 for Poly Medicure (industry 62.79) and 62.77 for Jubilant FoodWorks (industry 61.79). Only Jubilant FoodWorks trades at or above the industry multiple.
Which of these formulation major, infusion set maker and pizza chain stocks has the highest return on equity?
Ans. Jubilant FoodWorks has the highest return on equity at 18.69%, followed by Poly Medicure at 10.37% and Aurobindo Pharma at 9.25%.
What are the risks of investing in formulation major, infusion set maker and pizza chain stocks?
Ans. The main risks are debt and cash flow, consumer demand, input costs and quarterly trends. Jubilant FoodWorks has debt to equity of 2.14.
How did Aurobindo Pharma, Poly Medicure and Jubilant FoodWorks perform in Q1 FY27?
Ans. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. Poly Medicure reported revenue of Rs 558.79 crore, up 25.5% year on year. Jubilant FoodWorks reported revenue of Rs 2,588.34 crore, up 13.6% year on year, and net profit rose 6.0% to Rs 100.03 crore.
Do formulation major, infusion set maker and pizza chain stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.25% for Aurobindo Pharma, 0.22% for Poly Medicure and 0.28% for Jubilant FoodWorks, based on dividends declared for FY26.
How can I invest in formulation major, infusion set maker and pizza chain stocks in India?
Ans. You can buy formulation major, infusion set maker and pizza chain stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
